Form 4: ClearPoint Neuro Director Acquires Shares in Lieu of Fees

Director Timothy T. Richards acquired 995 shares of ClearPoint Neuro, Inc. common stock at $11.21 per share in lieu of fees owed under the company's Non-Employee Director Compensation Plan.

Summary

• On October 1, 2024, Timothy T. Richards, a director of ClearPoint Neuro, Inc., acquired 995 shares of common stock.
• The shares were acquired at a price of $11.21 per share.
• This transaction was made in lieu of fees owed to Richards under the company's Non-Employee Director Compensation Plan.
• Following the transaction, Richards beneficially owns 64,625 shares of ClearPoint Neuro, Inc.

Sentiment

Score: 6

Explanation: Neutral sentiment. The transaction is a routine part of director compensation and doesn't necessarily indicate a significant shift in the company's prospects.

Positives

• A director's decision to take compensation in the form of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This type of transaction, where directors receive stock in lieu of cash compensation, is relatively common in publicly traded companies. It aligns the director's interests with those of the shareholders.

Comparison to Industry Standards

• Comparing ClearPoint Neuro's director compensation plan to those of similar medical device companies would provide a benchmark for assessing its competitiveness and alignment with industry best practices.
• Companies like Medtronic, Stryker, and Boston Scientific have well-established director compensation plans that could serve as reference points.

Related Party Transactions

• The issuance of shares to Timothy T. Richards in lieu of fees is a related party transaction, as he is a director of the company.

Stakeholder Impact

• The transaction has a minor impact on shareholders, as it slightly increases the number of outstanding shares.
• The impact on employees, customers, suppliers, and creditors is negligible.

Key Dates